title: Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
abstract: OBJECTIVE
  This study was designed to evaluate the absolute bioavailability (F value) of 2-chlorodeoxyadenosine (cladribine; 2-CdA) after multiple oral administrations, and the intersubject variability after oral and 2-hour intravenous (IV) administration schedules in patients with malignancy.
  
  
  METHODS
  Patients with advanced malignancies were eligible. There were two treatment cycles; during cycle 1, patients received 2-CdA solution at 0.28 mg/kg/d orally under fasting conditions for 5 consecutive days concomitantly with omeprazole, and 4 weeks later during cycle 2 patients received 2-CdA as a 2-hour IV infusion of 0.14 mg/kg/d for 5 consecutive days. Serial blood samples for 2-CdA plasma levels were obtained after drug administrations on days 1 and 5 during each treatment cycle.
  
  
  RESULTS
  Ten patients completed cycles 1 and 2. The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively. For both oral and IV multiple administrations, there was no significant accumulation in maximum concentration (Cmax), and the intersubject variabilities (coefficient of variation [CV], approximately 40%) in Cmax and area under the concentration-time curve from 0 to 24 hours [AUC(0-24)] values were comparable for both routes on days 1 and 5. A three-compartment open model was applied to the plasma concentration data after oral and IV administrations and resulted in good agreement between observed and simulated concentration-time profiles. Neutropenia was the principal adverse event observed when 2-CdA was administered orally and IV.
  
  
  CONCLUSIONS
  The F value of 2-CdA after oral administration was approximately 37% and there were no cumulative differences in bioavailability observed on multiple dosing of the drug. The absorption and disposition characteristics of oral 2-CdA were linear and predictable with this dosing regimen.
authors.affiliation: Division of Hematology and Oncology, Scripps Clinic and Research Foundation, La Jolla, CA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Saven
authors.forename: W K
authors.initials: WK
authors.lastname: Cheung
authors.forename: I
authors.initials: I
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Moyer
authors.forename: T
authors.initials: T
authors.lastname: Johannsen
authors.forename: E
authors.initials: E
authors.lastname: Rose
authors.forename: R
authors.initials: R
authors.lastname: Gollard
authors.forename: M
authors.initials: M
authors.lastname: Kosty
authors.forename: W E
authors.initials: WE
authors.lastname: Miller
authors.forename: L D
authors.initials: LD
authors.lastname: Piro
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D001682:Biological Availability; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine